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Abstract: Molecular knowledge regarding the primary esophageal achalasia is essential for the early diagnosis and treatment of this
neurodegenerative motility disorder. Therefore, there is a need to find the main microRNAs (miRNAs) contributing to the mechanisms
of achalasia. This study was conducted to determine some patterns of deregulated miRNAs in achalasia. This case-control study was
performed on 52 patients with achalasia and 50 nonachalasia controls. The miRNA expression profiling was conducted on the esophageal
tissue samples using the next-generation sequencing (NGS). Differential expression of miRNAs was analyzed by the edgeR software. The
selected dysregulated miRNAs were additionally confirmed using the quantitative reverse transcription polymerase chain reaction (qRTPCR). Fifteen miRNAs were identified that were significantly altered in the tissues of the patients with achalasia. Among them, three
miRNAs including miR-133a-5p, miR-143-3p, and miR-6507-5p were upregulated. Also, six miRNAs including miR-215-5p, miR-216a-5p,
miR-216b-5p, miR-217, miR-7641 and miR-194-5p were downregulated significantly. The predicted targets for the dysregulated miRNAs
showed significant disease-associated pathways like neuronal cell apoptosis, neuromuscular balance, nerve growth factor signaling, and
immune response regulation. Further analysis using qRT-PCR showed significant down-regulation of hsa-miR-217 (p-value = 0.004)
in achalasia tissue. Our results may serve as a basis for more future functional studies to investigate the role of candidate miRNAs in the
etiology of achalasia and their application in the diagnosis and probably treatment of the disease.
Key words: Achalasia, microRNA, next-generation sequencing, expression profiling, bioinformatics

1. Introduction
Achalasia is a chronic neurogenic esophageal motility
disorder featured by impaired lower esophageal sphincter
(LES) laxity and disturbed peristalsis (Triadafilopoulos et
al., 2012). Its symptoms include progressive swallowing
disorder, regurgitation, esophageal chest pain, aspiration,
and eventually malnutrition (Sadowski et al., 2010).
According to a population-based study, achalasia
prevalence is more than 10/100,000, with a steady
increasing trend from 2.5/100,000 in 1996 to 10.8/100,000
in 2007 (Sadowski et al., 2010). Survival of the patients with
achalasia is significantly less than age-sex matched healthy

people (Sadowski et al., 2010). Most patients underwent
late diagnosis and ineffective treatment due to nonspecific
symptoms of the disease and the absence of noninvasive
diagnostic tests (Farrokhi and Vaezi, 2007).
The pathophysiology of achalasia is based on selective
loss of inhibitory neurons in the myenteric network,
which can interfere with the coordination of esophageal
peristalsis and LES relaxation during swallowing (Ghoshal
et al., 2012). Decreased levels of the nitric oxide synthase
(NOS) and vasoactive intestinal polypeptide (VIP) as
inhibitory neurotransmitters in the myenteric plexus
disrupt esophageal neuromuscular function in the patients
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with achalasia (Ates and Vaezi, 2015). Although the exact
mechanism of the disease is not fully understood, some
studies have shown evidence regarding the association
of the viral, autoimmune, and neurodegenerative factors
(Furuzawa-Carballeda et al., 2016; Park and Vaezi, 2005).
MicroRNAs (miRNA) are a group of small noncoding
RNAs which act as gene expression regulators in different
disease-related pathways (Bartel, 2004). The miRNA system
involves in various physiological and pathophysiological
processes and behaves as potential prognostic biomarkers
(Furer et al., 2010). Several studies showed the altered
miRNAs expression in various disorders, including cancers
(Fang et al., 2012), immune-mediated inflammatory
diseases (Singh et al., 2013; Tahamtan et al., 2016), and
nervous disturbances (Wang et al., 2014a).
Although few studies argue the association of
the pathogenesis of achalasia with neurological
communication, cholinergic signaling, and inflammation,
studying miRNAs expression helps us to understand
better the pathophysiology of achalasia. While
investigating the effects of miRNAs on the pathogenesis
of the abovementioned diseases has received considerable
attention, their effects on the development of achalasia
are still unclear. The present study performed the nextgeneration sequencing (NGS) with an analytical approach
to identify reliable candidate miRNAs associated with the
development of the disease.
2. Materials and methods
2.1. Participants and sampling
This matched case-control study was performed on 102
participants referred to the Digestive Diseases Research
Center (DDRC) in the Shariati Hospital in Tehran-Iran
between August 2015 and April 2016. All the patients with
primary esophageal achalasia referring to the clinic for
regular follow-up were recruited consecutively (N = 52).
These patients aged ≥18 years old were diagnosed based
on the clinical, radiological, endoscopic findings and
high-resolution manometry. All the patients received the
same pneumatic dilatation treatment and were classified
into excellent, good, moderate, and poor categories
according to the outcome. Patients in the excellent and
good categories were considered as good responses to the
treatment, and those in the moderate and poor categories
were considered as poor responses to the treatment
(Hasanzadeh et al., 2010). Controls were selected randomly
from the individuals without dysphagia or esophageal
lesions who visited the same clinic (N = 50). All the cases
and controls were matched by age (±5 years) and sex.
Participants underwent the endoscopic biopsy from the
LES by an expert clinician. The samples were stored at –80
ºC for the subsequent experiments. Patients with other

associated motility or nonmotility disorders, malignancy,
or coagulopathy were excluded from the study.
This study was approved by the Ethics Committee of
Golestan University of Medical Sciences (Ethics Code =
31078693122415). Participation in this study was optional.
Informed written consent was obtained from all of the
participants and their anonymity was preserved. The test
results were considered confidential and only available to
the physician and the moderator of the project.
2.2. RNA isolation and deep sequencing
Total RNA was extracted from all the samples (52 cases
and 50 controls) using the Trizol reagent according to
the manufacturers’ instructions (Invitrogen, Sweden). To
increase the experiment power, total RNAs were obtained
from each group of patients were pooled together (mixed
equally) and sent for miRNA sequencing (pooled sample
1, 2, 3, 4). For the controls, total RNAs were pooled equally,
and then two pooled samples were sent for miRNA
profiling (pooled sample 5, 6). In brief, each pooled sample
contained 15 and 25 extracted total RNAs of the patient
and the control groups respectively.
The samples were sent to BGI (Beijing Genomics
Institute) for miRNA sequencing. Bioanalyzer 2100
(Agilent, Santa Clara, CA) was employed to measure
the RNA Integrity Number (RIN) for each sample. The
samples with RIN greater than seven were considered for
sequencing. The RNA purification, library construction,
and sequencing procedures were conducted by the BGI
Company. Each library was single-end sequenced on
an Illumina HiSeq 4000 platform. The raw miRNA-Seq
data were deposited and released in the Sequence Read
Archive (SRA) database, with the BioProject accession
number of PRJNA616451.
2.3. Analysis of small RNA sequencing data (NGS data)
The FASTQC was used to perform primary quality control
of the miRNA-Seq data (version 0.11.51). Afterward,
low-quality reads and adapter sequences of raw data
were trimmed by the Trimmomatic software version
0.35 (Bolger et al., 2014) (parameters of trailing 20, max
info 18:0.90, and minimum length 18). Reads with the
length shorter than 18 bases were discarded after quality
trimming, and the remaining reads were mapped against
the Rfam database (Nawrocki et al., 2014) to eliminate
unwanted noncoding. RNAs (rRNAs, tRNAs, snRNAs,
and snoRNA). Subsequently, the remaining reads were
analyzed using the miRDeep2 software version 0.0.8 to
quantify known miRNAs and predict novel miRNAs
(Friedländer et al., 2011). For efficient read mapping, clean
reads in each sample were collapsed into a set of unique
sequences with read numbers counted. Then, the unique

Babraham Bioinformatics (2021). FastQC [online]. Website http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/ [accessed 0803-2016].
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sequences were aligned to the Ensembl GRCH37 human
genome (Ensembl Release 68) and miRNAs sequences
(miRBase database, version 21) (Kozomara and GriffithsJones, 2013). The aligned reads were quantified using the
default settings of the miRDeep2 software with only one
allowed mismatch within the read. On the other hand,
putative novel miRNAs were predicted using the default
settings in the miRDeep2 software. The predictions by
the miRDeep2 software were filtered, with a miRDeep2
score >1, the length of nucleotides ≥50, and the predicted
probability of being a miRNA > 60%. The difference in
miRNAs expression (fold change) was analyzed by the
edgeR package (version 1.4.5) in the R software. A fold
change with an adjusted p-value or false discovery rate
(FDR) less than 0.05 was considered statistically significant.
2.4. MiRNAs target prediction and gene enrichment
analyses
Potential target genes of the differentially expressed
miRNAs were predicted using the three target prediction
programs, including PITA (Kertesz et al., 2007), TargetSpy
(Sturm et al., 2010), and RNAhybrid (Rehmsmeier et al.,
2004). If a gene was predicted by at least two programs,
it was considered as a putative target. Since each program
uses various algorithms to predict miRNA targets and
has different levels of sensitivity and specificity, using
the combination of them reduced the false positive. We
applied the default parameters of each program for target
prediction. The 3’UTR sequences were recovered by the
Ensembl BioMart2 and then, were used for prediction.
Finally, Gene Ontology (GO) and Kyoto Encyclopedia
Genes and Genomes (Qiu, 2013) were applied to analyze
the potential function and pathway of target genes.
2.5. Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) analysis
For more confirmation, the expression levels of the
dysregulated candidate miRNAs were measured in the
esophageal tissues of the patients with achalasia (N =
28) and control individuals (N = 32) by the ABI 7300
real-time PCR machine (Applied Biosystems, USA). The
process of cDNA synthesis of miRNAs was performed by
the Reverse Transcription System Kit (ZistRoyesh, Iran)
with a miR-specific stem-loop primer (MohammadiYeganeh et al., 2013). The SNORD47 was measured as
an internal normalization control using the 2-dct method.
For qRT-PCR statistical analysis, differences between the
two groups were tested by Student’s t-test and the Mann–
Whitney U test (based on normality of data distribution)
in the SPSS statistical software version 16.0. The difference
with a probability value less than 0.05 was considered
statistically significant.
Ensembl BioMart database [online]. Website http://rfam.xfam.org/
[accessed 10-04-16].
2
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3. Results
3.1. Esophageal tissues of the patients with achalasia expressed MiRNA profile different from the controls
Table 1 summarizes the clinical information of the patients.
As demonstrated in Table 1, there is no significant difference
in age (p-value = 0.48) and sex (p-value = 0.43) between
the cases and controls. The miRNA sequencing results
were compared between three groups: good response
group including pooled samples 1 and 2 (those with good
and excellent response to the dilatation treatment), poor
response group consisting of pooled samples 3 and 4
(those with moderate and poor response to the dilatation
treatment), and pooled samples 5 and 6 that were merged
into control group to perform the transcriptome analysis
based on the clinicians’ recommendation (Table 2). It was
attempted to increase the statistical power through postprocessing replication for each group.
The miRNA expression profiling analysis showed that
15 miRNAs were significantly differentially expressed in
the tissues of the patients with achalasia (good or poor
response groups) compared to the controls. Besides, our
findings indicated that most of the dysregulated miRNAs
(11 miRNAs) were downregulated and only four miRNAs
were upregulated in the tissues of the patients with
achalasia. Three miRNAs were significantly upregulated
in both good and poor response group compared to the
controls; miR-133a-5p (adjusted p-value < 0.001 for good
response group and adjusted p-value = 0.005 for poor
response group), miR-143-3p (adjusted p-value = 0.001
for good response group and adjusted p-value = 0.011 for
poor response group) and miR-6507-5p (adjusted p-value
= 0.001for good response group and adjusted p-value =
0.016 for poor response group). Besides, the NGS data
showed hsa-miR-3609 was significantly upregulated only in
a good response group compared to the controls (adjusted
p-value = 0.021). Furthermore, we found six miRNAs
that were downregulated significantly in both good and
poor response groups (Figure1). These were miR-215-5p,
miR-216a-5p, miR-216b-5p, miR-217 and miR-7641 with
adjusted p-value < 0.001 and miR-194-5p (adjusted p-value
= 0.01 for good response group and adjusted p-value
= 0.005 for poor response group). Moreover, the good
response group showed significant downregulation in the
expression of four miRNAs, including hsa-miR-135a-5p,
hsa-miR-4488, hsa-miR-122-5p, and hsa-miR-4449. On
the other hand, the significant downregulation of hsamiR-383-5p (adjusted p-value =0.001) was seen in the
poor response achalasia group compared to the controls
(Table 3). This study did not detect significant differential
expression in any of the miRNAs between two groups of
patients with achalasia (good and poor response groups)
regarding the treatment outcome.
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Table 1. Clinical data for 52 achalasia patients and 50 controls.
Characteristic

Patients †

Controls †

p-value

Mean age (SD ), year

43.5 (1.6)

45.8 (1.6)

0.48

Male/female no. (% male)
Vantrappen classification§
Excellent
Good
Moderate
Poor
Achalasia subtype¶
Type 1
Type 2
Type 3
Mean duration (months) of symptoms (SD)
Baseline symptoms
Dysphagia
Chest pain
Regurgitation

31/21 (59.6)
n (%)
15 (28.8)
15 (28.8)
12 (23.1)
10 (19.2)
n (%)
9 (17.3)
42 (80.8)
1 (1.9 )
32.34 (2.06)
n (%)
43 (82.7)
7 (13.5)
2 (3.8)

26/24 (52)

0.43

‡

Unless otherwise indicated data are expressed as number (percentage) of patients. Percentages
have been rounded and might not total 100.
‡
SD: Standard deviation.
§
Vantrappen classification: Excellent, indicates no symptoms; Good, symptoms occurring less
than once a week; Moderate, symptoms occurring more than once weekly; and Poor, persistent
symptoms (Vantrappen and Hellemans, 1980).
¶
Achalasia subtype: Type 1 (classic) with minimal contractility in the esophageal body, type 2
with intermittent periodsof panesophageal pressurization, and type 3 (spastic) with premature
or spastic distal esophageal contractions (Kahrilas et al., 2015).
†

Table 2. Next-generation sequencing read counts and mapping result for individual samples.
Post processing
Clinical outcome after dilatation treatment Sample ID
Total Reads
grouping
Excellent
Pooled sample1 30378288
Treat 1
Good response
Good
Pooled sample2 26809904
Treat 2
Treat 3

Poor response
Without treatment / Control

Mapped
Mapped (%)
Reads
15879232 0.523
13712314 0.511

Fair

Pooled sample3 29249887

14814455 0.506

Poor

Pooled sample4 30445887

16872768 0.554

Control 1

Pooled sample5 24835372

10948105 0.441

Control 2

Pooled sample6 29473046

13101058 0.445

3.2. Functional annotation of the candidate miRNAs
The biological process of GO and KEGG pathways of
the 15 candidate miRNAs were analyzed based on the
biological process. As detailed in Table 4, we introduced a
list of the most significantly enriched terms and pathways
of the target genes of candidate miRNAs involved in
achalasia. Interestingly, GO analysis showed that the
differentially expressed genes associated with the neuron
apoptotic process (adjusted p-value = 0.004), neuronal
death (adjusted p-value = 0.006), and immune response

regulation (adjusted p-value = 0.008) were targeted by
hsa-miR-143-3p. We found that the genes related to the
cellular response to oxidative stress (adjusted p-value
= 0.011), cellular aging (adjusted p-value = 0.011), axon
regeneration and development (adjusted p-value =
0.031) and myelination (adjusted p-value = 0.031) were
significantly enriched by the hsa-miR-217. Moreover,
KEGG analysis showed that the genes involved in Glioma
(adjusted p-value = 0.0001) and the Sphingolipid signaling
pathway (adjusted p-value = 0.0006) were the most highly
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Figure 1. Candidate tissue miRNAs significantly differentially expressed in the
patients with achalasia compared to the controls. Nine candidate miRNAs are
common in samples of two achalasia groups. Good response group: achalasia
patients with a good response to the pneumatic dilatation treatment. Poor
response group: achalasia patients with poor response to the pneumatic dilation
treatment.
Table 3. Fifteen significant upregulated and downregulated miRNAs in the achalasia tissues (Good response
group and Poor response group) versus control tissues.

MicroRNA
hsa-miR-217

Treat 1
FC†

log2FC†

↓0.020

–5.644

Treat 2
Adjusted
p-value
FC†
p-value
3.98E-10 2.46E-07 ↓ 0.31

log2 FC† p- value
–1.69

A p-value*

9.68E-09 1.5E-06

hsa-miR-216a-5p ↓ 0.062 –4.011

1.05E-09 2.65E-07

↓ 0.047 –4.411

1.02E-10 3.14E-08

hsa-miR-7641

1.28E-09 2.65E-07

↓ 0.160 –2.644

2.28E-09 4.71E-07

2.06E-09 3.18E-07

↓ 0.04

↓ 0.155 –2.689

hsa-miR-216b-5p ↓ 0.08
hsa-miR-215-5p

–3.644

↓ 0.240 –2.059

–4.644

7.52E-13 4.65E-10

8.98E-07 0.000111 ↓ 0.193 –2.373

2.39E-08 2.95E-06

hsa-miR-135a-5p ↓ 0.173 –2.531

2.14E-06 0.00022

hsa-miR-194-5p

↓ 0.368 –1.442

0.000174 0.010725 ↓ 0.353 –1.502

7.62E-05 0.005888

hsa-miR-4488

↓ 0.323 –1.630

0.000571 0.029432 -

-

-

-

-

-

hsa-miR-122-5p

↓ 0.231 –2.114

0.000723 0.03438

-

-

-

-

hsa-miR-4449

↓ 0.302 –1.727

0.000835 0.036864 -

-

-

-

2.89E-06 0.000255 ↑ 19

4.248

7.62E-05 0.005888

1.74E-05 0.001345 ↑ 5.173 2.371

0.000166 0.011374

hsa-miR-133a-5p ↑ 35
hsa-miR-143-3p

5.129

↑ 6.702 2.744

hsa-miR-6507-5p ↑ 44

5.459

2.36E-05 0.00162

hsa-miR-3609

↑ 4.6

2.202

0.00038

0.021343 -

hsa-miR-383-5p

-

-

-

-

↑ 24

4.585

0.000261 0.016122

-

-

↓ 0.133 –2.910

-

1.28E-05 0.001317

FC, Fold change;*A p-value§, Adjusted p-value.

†

represented pathways enriched by the hsa-miR-143-3p.
The genes associated with cancers, including non-small
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Table 4. The most significant enriched terms (potential function and pathway of target genes) based on biological process GO†
enrichment (white rows) and KEGG‡ pathway (gray rows) of the miRNAs associated with achalasia.
miRNA

hsamiR-217

hsa-miR216b-5p

Enriched Term

Target genes

A p-value*

Nonsmall cell lung cancer- Homo sapiens- hsa05223

E2F3;KRAS;FOX3;FHIT

0.004

Endometrial cancer- Homo sapiens- hsa05213

TCF7L2;PTEN;KRAS;FOXO3

0.004

Negative regulation of cell aging (GO:0090344)

PTEN;SIRT1;MARCH5

0.011

Cellular response to oxidative stress (GO:0034599)

NR4A2;TP53INP1;FOXO3;SIRT1;HIF1A;EZH2

0.011

Prostate cancer- Homo sapiens-hsa05215

TCF7L2;PTEN;E2F3;KRAS

0.016

Regulation of myelination (GO:0031641)

TCF7L2;PTEN;TNFRSF21

0.041

Melanoma- Homo sapiens- hsa05218

CDK6;CDK4;MAPK1;KRAS;FGF10

0.034

Pathways in cancer-Homo sapiens-hsa05200

CDK6;FZD5;TPM3;CDK4;COL4A4;FZD9;TCEB2;MAPK1;
KRAS;FGF10

0.036

SMAD1;FZD5;FZD9;MAPK1;LHX5;KRAS

0.036

CDK6;CDK4;MAPK1;KRAS

0.037

Signaling pathways regulating pluripotency of stem cellsHomo sapiens_hsa04550
Nonsmall cell lung cancer-Homo sapiens-hsa05223

hsa-miR215-5p

Cell cycle-Homo sapiens-hsa04110
Glioma-Homo sapiens- hsa05214
Sphingolipid signaling pathway- Homo sapiens- hsa04071
MicroRNAs in cancer- Homo sapiens-has 05206

hsa-miR143-3p

hsa-miR6507-5p

hsa-miR135a-5p

RB1;CDKN2D;CDKN2A;BUB1B;CDC7;TTK;CDC14A;AN
APC10;CDC20;ORC4;ORC1;CCNE1;RAD21;MCM3;MCM
6;MAD2L1
PDGFRA;MDM2;AKT1;MAPK1;BRAF;CALM3;KRAS;HR
AS;IGF1R
CERS4;SGPL1;SPTLC2;PPP2R5E;BCL2;AKT1;MAPK1;KRA
S;TNF;HRAS
TRIM71;PDGFRA;DNMT3A;PTGS2;MAPK7;ERBB3;FSCN
1;MDM2;BCL2;MAPK1;KRAS;HRAS;CD44

0.012
-1.84E-05
-6.69E-05
0.0007
0.0012

Nonsmall cell lung Cancer-Homo sapiens-hsa05223

AKT1; MAPK1; BRAF; KRAS; FHIT; HRAS

Colorectal Cancer-Homo sapiens-hsa05210

SMAD3; BCL2; AKT1; MAPK1; BRAF; KRAS

Bladder Cancer-Homo sapiens-hsa05219

MDM2; MAPK1; BRAF; KRAS; HRAS

Regulation of neuron death (GO:1901214)

ERBB3;UBE2V2;BCL2;AKT1;XIAP;KRAS;BRAF;HRAS;TN
F;BB

Regulation of neuron apoptotic process (GO:0043523)

ERBB3;UBE2V2;BCL2;XIAP;KRAS;BRAF;HRAS;TNF;BBC3

Negative regulation of neuron death (GO:1901215)

ERBB3;UBE2V2;BCL2;AKT1;XIAP;KRAS;BRAF;HRAS

Immune response regulating cell surface receptor signaling
pathway GO:0002768)

PDGFRA;NCKAP1;PLEKHA1;YWHAB;LIMK1;ERBB

0.0080

cytokinesis_(GO:0000910)

RACGAP1;PRC1;NEK7;MYH9;CEP55;RHOB

0.033

Jak STAT signaling pathway-Homo sapiens-hsa04630

PIAS4;MYC;MPL;BCL2;STAT6;JAK2

0.002

Signaling pathways regulating pluripotency of stem cellsHomo sapiens-hsa04550

BMPR2;APC;MYC;JAK2;SMAD5;SKIL

0.002

Colorectal cancer-Homo sapiens-hsa05210

APC;MYC;BCL2;BIRC5

0.004

MicroRNAs in cancer-Homo sapiens-hsa05206

MARCKS;BMPR2;APC;ROCK1;MYC;BCL2;IRS2

0.004

TGF beta signaling pathway-Homo sapiens-hsa04350

BMPR2;ROCK1;MYC;SMAD5

0.008

Cellular response to BMP stimulus (GO:0071773)

HEYL;GATA6;SMAD5

0.031

Response to BMP (GO:0071772)

HEYL;GATA6;SMAD5

0.031

neuron_projection_regeneration_(GO:0031102)

BCL2;APOA1;JAK2

0.031

Axon development (GO:0061564)

BCL2;APOA1;JAK2

0.031

Axon regeneration (GO:0031103)

BCL2;APOA1;JAK2

0.031

Positive regulation of ntrinsic apoptotic signaling pathway
(GO:2001244

PIAS4;SIAH1;BCL2;SKIL

0.031

0.0015
0.0019
0.004
0.004
0.006
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Table 4. (Continued.)
Pathways in cancer-Homo sapiens-hsa05200
hsamiR-3609

Proteoglycans in cancer Homo sapiens hsa05205
Endocytosis-Homo sapiens hsa04144
Focal adhesion- Homo sapiens-hsa04510

hsa-miR194-5p

ITGB1;EGLN3;PRKCB;F2R;FZD9;XIAP;HIF1A;IGF1R;TGF
BR2;BMP2;CCND1;MDM2;MAPK1;CRK;APPL1;F2RL3
ITGB1;CCND1;PRKCB;CAV1;FZD9;MDM2;RRAS2;MAPK
1;HIF1A;THBS1;IGF1R
SH3GLB1;HSPA8;RAB5B;RAB4A;ZFYVE9;SH3KBP1;CAV1;
F2R;EPS15L1;IGF1R;TGFBR2;RAB11FIP1;MDM2
RAP1B;ITGB1;CCND1;PRKCB;CAV1;XIAP;PAK6;MAPK1;
CRK;THBS1;IGF1R

0.020
0.020
0.020
0.020

Adherens junction- Homo sapiens-hsa04520

TJP1;EP300;RAC1;IGF1R

0.048

Proteoglycans in cancer-Homo sapiens-hsa05205

CAV1;FZD6;RAC1;HBEGF;IGF1R

0.049

Focal adhesion- Homo sapiens-hsa04510

CAV1;TLN2;RAC1;IGF1R;ITGA9

0.049

HIF-1 signaling pathway-Homo sapiens-hsa04066

CDKN1B;EP300;RBX1;IGF1R

0.049

GO, Gene Ontology; ‡KEGG, Kyoto Encyclopedia of Genes and Genomes; *A p-value, Adjusted p-value.

†

prostate (adjusted p-value = 0.004 for hsa-miR-217),
colorectal (adjusted p-value = 0.001 for hsa-miR-143-3p),
bladder (adjusted p-value = 0.001 for hsa-miR-143-3p)
and endometrial cancers (adjusted p-value = 0.004 for
hsa-miR-217) were significantly enriched by the predicted
target genes (Table 4).
3.3. Novel predicted miRNAs in the esophageal tissue
Interestingly, the data analysis showed novel potential
miRNA transcripts in the esophageal tissues were expressed
in at least two different pooled samples with mean read
counts greater than five in each group. All the rRNAs and
tRNAs were excluded by Rfam database (Nawrocki, et
al., 2014) and the identified novel miRNAs possessed the
criteria of secondary structure in the RNA fold change.
Thirty-six novel candidate miRNAs were identified with
mammalian homologues using this approach (Table
S1), but none of them was significantly changed in the
achalasia. GO analysis showed that eight novel miRNAs
are significantly related to the neurotransmission
process (adjusted p-value = 0.03), axon development and
regeneration (adjusted p-value = 0.02), cellular response
to nerve growth factor (adjusted p-value = 0.03), and
inflammation process (Table 5).
3.4. Validation of the NGS results by the qRT-PCR analysis
Three candidate miRNAs (hsa-miR-217, hsa-miR-1433p, and hsa-miR-133a-5p), with the highest expression
changes, were selected from the NGS data to confirm
the gene expression changes. The qRT-PCR was used
to validate the results of NGS. The qRT-PCR findings
revealed a significant decline of hsa-miR-217 expression
in the achalasia tissues compared to the controls (p-value
= 0.004). These findings validated the results of the same
comparison conducted by the NGS method. The qRT-PCR
findings of hsa-miR-143-3p and hsa-miR-133a-5p, similar
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to the NGS results, showed upregulated expression in the
tissues of the patients with achalasia but, contrary to NGS,
these findings were not significant (p-value = 0.457 and
p-value = 0.840 respectively) (Figure 2).
4. Discussion
To the best of our knowledge, this study is the first study in
which the miRNA expression in the tissues of the patients
with achalasia was compared to the controls using the NGS
approach. The complete pattern of the miRNAs associated
with the achalasia was obtained using the NGS approach.
Fifteen miRNAs had significant differential expression
in the esophageal tissues of the patients with achalasia
compared to the controls. It was confirmed that miR-217
was downregulated significantly, and miR-143-3p and
hsa-miR-133a-5p were upregulated (p-value > 0.05) in the
achalasia tissues using the stem-loop qPCR as similarly
observed in the NGS results. In a recent study using the
microarray method, Shoji et al. showed that only two
miRNAs (miR‑361‑5p and miR‑130a) were upregulated in
patients with achalasia, which is contrary to the present
study. This difference may be attributed to the different
methods used in each study for miRNA expression
analysis. Moreover, they used middle esophageal mucosa
for sampling, which could potentially have different gene
expression from the LES (Shoji et al., 2017). Another
study that evaluated the miRNA expression profiling by
the microarray demonstrated upregulated expression of
hsa-miR-133a-5p in achalasia tissue in line with our study
(Palmieri et al., 2019). Both previous studies used the
microarray method for sequencing. The NGS platforms
have higher sensitivity and dynamic amplitude than
microarrays with higher sequencing depth (Motameny et
al., 2010). Furthermore, the NGS produces a more accurate
and reliable sequence, even if the individual reads are less
accurate (Kulski, 2016).
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Table 5. The most significant enriched terms (potential function and pathway of target genes) based on biological process GO†
enrichment of the novel candidate miRNAs in the esophageal tissues.
miRNA

2:46348793..46348872

3:186787298..186787358
6:104646203...104646269

Positive_regulation_of_neurotransmitter_transport_(GO:0051590)

A
p-value*
0.024

Positive_regulation_of_neurotransmitter_secretion_(GO:0001956)

0.024

Enriched Term

Anterograde_axon_cargo_transport_(GO:0008089)
Axon_cargo_transport_(GO:0008088)

Target genes

DTNBP1

0.03

Regulation_of_neurotransmitter_transport_(GO:0051588)

0.03

Neuroepithelial_cell_differentiation_(GO:0060563)

MITF

Cellular_response_to_interleukin-6_(GO:0071354)
Interleukin-6-mediated_signaling_pathway_(GO:0070102)
Positive_regulation_of_interleukin8_biosynthetic_process_(GO:0045416)
Regulation_of_interleukin-8_production_(GO:0032677)

15:60128283...60128360

0.046
0.039

GALT

0.027
0.04

PRG3

0.031
0.031

Neuron_projection_regeneration_(GO:0031102)

0.02

Axon_development_(GO:0061564)

0.02

Axon_regeneration_(GO:0031103)

0.02

Anterograde_axon_cargo_transport_(GO:0008089)

0.02

Neurofilament_cytoskeleton_organization_(GO:0060052)

0.02

Axon_cargo_transport_(GO:0008088)

0.02

Response_to_axon_injury_(GO:0048678)

0.02

Positive_regulation_of_axonogenesis_(GO:0050772)
Negative_regulation_of_neuron_apoptotic_process_(GO:0043524)

20:38425194..38425268

0.03

Regulation_of_neurotransmitter_secretion_(GO:0046928)

Response_to_interleukin-6_(GO:0070741)
7:53776229...53776317

0.024

NEFL

0.024
0.036

Regulation_of_axonogenesis_(GO:0050770)

0.036

Negative_regulation_of_neuron_death_(GO:1901215)

0.037

Regulation_of_neuron_apoptotic_process_(GO:0043523)

0.04

Positive_regulation_of_neuron_differentiation_(GO:0045666)

0.044

Regulation_of_neuron_death_(GO:1901214)

0.044

Regulation_of_neuron_projection_development_(GO:0010975)

0.046

Positive_regulation_of_neurogenesis_(GO:0050769)

0.047

Cellular_response_to_nerve_growth_factor_stimulus_(GO:1990090)

RAP1A

0.032

Response_to_nerve_growth_factor_(GO:1990089)
Positive_regulation_of_calcium_ion_transmembrane_transporter_activity_
(GO:1901021)
Negative_regulation_of_neurotransmitter_transport_(GO:0051589)

RAP1A

0.032

ANK2

0.032

RAP1A

0.032

Nerve_growth_factor_signaling_pathway_(GO:0038180)

RAP1A

0.032

Negative_regulation_of_neurotransmitter_secretion_(GO:0046929)

RAP1A

0.032

Regulation_of_neurotransmitter_secretion_(GO:0046928)

RAP1A

0.047

269

GHOLIPOUR et al. / Turk J Biol
Table 5. (Continued.)

6:77781479...77781527

12:29562570..29562639

Regulation_of_intrinsic_apoptotic_signaling_pathway_by_p53_class_
mediator_(GO:1902253)
Negative_regulation_of_signal_transduction_by_p53_class_mediator_
(GO:1901797)
Regulation_of_signal_transduction_by_p53_class_mediator_(GO:1901796)

0.004
0.005
RRM2B

0.006

Regulation_of_intrinsic_apoptotic_signaling_pathway_(GO:2001242)

0.014

Negative_regulation_of_apoptotic_signaling_pathway_(GO:2001234)

0.018

Regulation_of_apoptotic_signaling_pathway_(GO:2001233)
Calcium-mediated_signaling_using_intracellular_calcium_source_
(GO:0035584)
Regulation_of_interleukin-8_biosynthetic_process_(GO:0045414)

0.028
HOMER2

0.039

PRG3

0.039

Mast_cell_activation_involved_in_immune_response_(GO:0002279)

PLA2G3

0.039

Positive_regulation_of_interleukin-8_biosynthetic_process_(GO:0045416)

PRG3

0.039

Axoneme_assembly_(GO:0035082)

PLA2G3

0.042

GO, Gene Ontology; *A p-value, Adjusted p-value.

†

Figure 2. Relative expression of hsa-miR-217(p-value = 0.004), hsa-miR-143-3p (p-value = 0.457), and hsa-miR-133a-5p (p-value
= 0.840) in the esophageal tissues of the patients with achalasia compared to the controls by the quantitative reverse transcription
polymerase chain reaction (qRT-PCR) validation. Relative expression was calculated using 2-dct formula. Significant differences (p-value)
have been shown in each graph.

Functional annotation revealed that many miRNAs
determined in our study are involved in neuronal cell
apoptosis (hsa-miR-143-3p), myelination process (hsamiR-217), and neuronal regeneration (hsa-miR-135a-5p).
In accordance with our findings, a previous study showed
the mechanism of esophageal dysfunction in response
to neuronal destruction in patients with Parkinson’s
disease (Qualman et al., 1984). Moreover, the current
study found that hsa-miR-143-3p targeted the immune
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system which was shown to be dysregulated in achalasia
patients. Although the etiology of primary esophageal
achalasia remains unknown, several hypotheses suggest
that inflammation and autoimmunity are associated
with its pathogenesis (Hirano, 2006). The histopathology
analysis of the esophageal tissues, indicated lymphocytic
infiltration, myenteric inflammation, and aganglionosis
during the achalasia (Sodikoff et al., 2016). The cytotoxic
autoimmune responses can potentially trigger progressive
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neuronal apoptosis in the achalasia tissues (Kahrilas
and Boeckxstaens, 2013). The evidence suggests that
miRNAs play an important role in the development of
neurodegenerative diseases (Kye and Inês do Carmo,
2014).
Some of the miRNAs that were significantly
differentially expressed in the current study were previously
reported as cancer-related miRNAs. For example, miR217, assuming to have tumor suppressor function;
has been reported downregulated in several cancers
such as gastric cancer (Chen et al., 2015), pancreatic
ductal adenocarcinoma (Vychytilova-Faltejskova et al.,
2015), Esophageal Squamous Cell Carcinoma (ESCC)
(Wang et al., 2015b), and colorectal cancer (Wang et al.,
2015a). Moreover, similar to this study, reduced miR216 expression was reported in other diseases, such as
nonsmall cell lung cancer (Wang et al., 2014b), ESCC
(Dong et al., 2016), nasopharyngeal carcinoma (Deng et
al., 2011), and hepatocellular carcinoma (Liu et al., 2015).
The tumor suppressor role of miR-217 and miR-216 may
justify the high prevalence of esophageal cancer in patients
with achalasia. Despite the pathological differences
between neurodegenerative diseases (such as achalasia)
and cancers, new evidence suggests that they have similar
regulatory mechanisms (Grasso et al., 2014).
The present study indicated the upregulation of hsamiR-143-3p in the achalasia tissues of the patients. The
upregulation of miR-143 in the CD4+T cells, highlights
the importance of this miRNA in autoimmune diseases
(Martínez-Ramos et al., 2014). This finding is in agreement
with the role of autoimmunity in the formation of achalasia.
The biological process of GO and KEGG assessments
in this study demonstrated that phosphatase and tensin
homolog (PTEN) and Sirtuin 1 (SIRT1) could be
significant targets of miR-217 in the achalasia (Table
4). Some studies showed that PTEN has a direct role in
neurodegeneration under oxidative stress conditions
(Li et al., 2013b; Morris et al., 2010). SIRT1 levels are
associated with neurodegenerative diseases which have a
progressive and severe reduction in neuronal cells (Kim et
al., 2007). These findings could be in line with the role of
neurodegeneration in the development of achalasia.
Interestingly, our findings identified some genetic
factors related to the candidate miRNAs similar to other
studies which were associated with achalasia. For instance,
the HLA genes which showed to be targeted by miR122-5p in this study related to achalasia in another study
(Ruiz-de-León et al., 2002). In the current study, some
immune modulator genes, including Interleukin 10(IL10) and Interleukin 23 Receptor (IL-23R), were predicted
to be targeted by hsa-miR-143-3p and hsa-miR-216a-5
respectively (De León et al., 2010; Palmieri et al., 2016).
Accordingly, these findings highlight the role of immunity

and inflammation in the initiation and progression of
achalasia (Table S2).
This research showed that miR-383-5p was
downregulated in the patient with achalasia who had a
poor response to the dilatation treatment. This miRNA
might play a potential prognostic role in the prediction of
the response to the treatment in patients with achalasia.
However, further studies could confirm this finding. Other
studies introduced the hsa-miR-383 as a tumor suppressor
with a decreased level in the glioma, medulloblastoma,
and testicular embryonal carcinoma cells (Li et al., 2013a;
Lian et al., 2010; Xu et al., 2015; Xu et al., 2014). Our
results demonstrated that dysregulated miR-216b could
target the tropomyosin (TPM), the gene which encodes
the beta-tropomyosin with an important role in the
regulation of the calcium-dependent muscle contraction.
A study showed the changes in the TPM expression on the
achalasia tissues (Palmieri et al., 2016). These findings may
emphasize the neuromuscular process in the pathogenesis
and development of the achalasia (Table 4).
Other findings indicated that has-miR-135 was
downregulated only in the patients with a good response
to the treatment. Some studies showed that the induction
of miR-135a expression in different types of cancers could
suppress cell proliferation through target genes (c-MYC,
STAT6, SMAD5, and BMPR2). Some research introduced
miR-135a as a potential predictor of treatment outcome
in some cancers (Yamada et al., 2013; Ahmad et al., 2018).
The current study confirmed that these target genes could
be considered as significant targets of has-miR-135 in
achalasia (Table 4).
This investigation found that Caveolin1 (CAV1)
involving in the calcium signaling pathway could be a
significant target of hsa-miR-3609 and hsa-miR-194-5p
which are differentially expressed in the achalasia tissues
of the patients. This finding is in line with a study that
showed the CAV1 target gene was differentially expressed
in the achalasia tissues with a possible function related
to the achalasia pathogenesis (Palmieri et al., 2016).
It is generally accepted that calcium channel blockers
can support LES relaxation and esophageal peristalsis
in patients with achalasia (Dughera et al., 2011). This
provides further support for the role of candidate miRNAs
in the etiology of achalasia.
5. Conclusion
In conclusion, the results of the current study provide
a comprehensive analysis of miRNA expression in the
achalasia and may be used as a basis for future studies to
investigate the role of candidate miRNAs in the etiology
of achalasia. A significant downregulation was observed
in the hsa-miR-217 in the LES samples of the achalasia
patients with significant enrichment in myelination
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process ontology. Furthermore, the NGS miRNA
expression profiling might be a suitable platform to classify
the achalasia into different response groups concerning
the outcome of dilatation treatment.
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